Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessationadmin2021-11-22T15:02:03-05:00November 23rd, 2021|Press Release| Read More
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)admin2021-11-21T20:05:19-05:00November 22nd, 2021|Press Release| Read More
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Developmentadmin2021-11-09T14:09:55-05:00November 9th, 2021|Press Release| Read More
Achieve Life Sciences Announces Participation in November Investor Conferencesadmin2021-11-03T20:09:05-05:00November 4th, 2021|Press Release| Read More
Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline’s Second Planned Indication for Nicotine E-cigarette Cessationadmin2021-11-01T16:35:00-05:00November 2nd, 2021|Press Release| Read More
Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021admin2021-10-25T14:20:27-05:00October 26th, 2021|Press Release| Read More
Achieve Life Sciences to Participate in Upcoming Investor Conferencesadmin2021-09-09T13:30:32-05:00September 15th, 2021|Press Release| Read More
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conferenceadmin2021-10-19T16:08:07-05:00September 14th, 2021|Press Release| Read More
Achieve Life Sciences to Participate in Two Upcoming Investor Conferencesadmin2021-09-07T20:47:36-05:00September 9th, 2021|Press Release| Read More
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awardsadmin2021-08-11T19:52:14-05:00August 13th, 2021|Press Release| Read More